TNGX - Company ID 0001819133
The table below shows Tango Therapeutics, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $53.81M | $3.18M | $5.39M | $11.61M | $19.88M |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $33.53M | $30.82M | $32.81M | $36.44M | $33.26M | $38.65M |
Tango Therapeutics, Inc. reported annual revenue of $62.38M for fiscal year 2025. That is up 48.3% from $42.07M in fiscal 2024. Over the 6 fiscal years shown, annual revenue grew from $7.66M (FY 2020) to $62.38M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $15.23M |
| $8.92M |
| $11.34M |
| $11.48M |
| $11.22M |
| $10.77M |
| Operating income | -$48.77M | $14.07M | -$40.97M | -$42.53M | -$32.88M | -$29.55M |
| Income tax | $1.00K | -$10.00K | $35.00K | $34.00K | $54.00K | $65.00K |
| Net income | -$45.51M | $15.88M | -$38.85M | -$39.88M | -$29.17M | -$25.55M |
| EPS (diluted) | -$0.32 | $0.13 | -$0.35 | -$0.36 | -$0.27 | -$0.24 |